Advertisement
Canada markets open in 1 hour 50 minutes
  • S&P/TSX

    21,953.80
    +78.01 (+0.36%)
     
  • S&P 500

    5,509.01
    +33.92 (+0.62%)
     
  • DOW

    39,331.85
    +162.33 (+0.41%)
     
  • CAD/USD

    0.7313
    +0.0002 (+0.02%)
     
  • CRUDE OIL

    82.79
    -0.02 (-0.02%)
     
  • Bitcoin CAD

    82,238.45
    -3,577.92 (-4.17%)
     
  • CMC Crypto 200

    1,298.22
    -36.70 (-2.75%)
     
  • GOLD FUTURES

    2,354.30
    +20.90 (+0.90%)
     
  • RUSSELL 2000

    2,033.87
    +3.81 (+0.19%)
     
  • 10-Yr Bond

    4.4360
    -0.0430 (-0.96%)
     
  • NASDAQ futures

    20,250.75
    -4.50 (-0.02%)
     
  • VOLATILITY

    12.12
    +0.09 (+0.75%)
     
  • FTSE

    8,168.08
    +46.88 (+0.58%)
     
  • NIKKEI 225

    40,580.76
    +506.07 (+1.26%)
     
  • CAD/EUR

    0.6794
    -0.0006 (-0.09%)
     

PRESS DIGEST- Financial Times - Oct. 10

Oct 10 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy.

Headlines

- Clydesdale Bank charged unfair fees to small businesses, High Court told

- Israel's central bank to sell $30 bln of foreign reserves to support shekel

- Metro Bank backs branch model after striking financing deal

- EU regulators to order Illumina to sell $8 bln cancer treatment group

Overview

- Four businesses, which represent a much wider group action of 900 small firms, are suing National Australia Bank and Clydesdale Bank for charging unfair break fees on loans sold to small businesses.

ADVERTISEMENT

- The Bank of Israel said on Monday it plans to sell up to $30 billion of dollar reserves to support the shekel after the market fallout from Hamas' attacks, however, despite the central bank's announcement shekel slumped to a seven-year low against the dollar, weakest level since 2016.

- After striking a financing deal that will give the UK challenger bank breathing space and fill a capital hole that had prompted talks with regulators, UK's Metro Bank has insisted that its branch-based model is the right one.

- EU regulators will order US biotech Illumina to sell cancer test developer Grail after it bought the $8bn company without the approval of Brussels, a step intended to deepen the punishment for Illumina after Brussels fined the world's largest gene-sequencing company 432 million euros ($456.80 million) in July for defying what regulators described as a "cornerstone" of their authority. ($1 = 0.9457 euros) (Compiled by Bengaluru newsroom)